FDA-approved label information Reproduced from the FDA Structured Product Label via the openFDA API. Label version: July 30, 2026. Status Human Prescription Drug Brand names Ozempic Route Subcutaneous Drug class GLP-1 Receptor Agonist [EPC] Boxed warning WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically … Continue reading Semaglutide